Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...
Phase 2b study to evaluate novel inhaled therapeutic in patients with inadequately controlled asthma despite medium-to-high dose ICS/LABA therapy BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a ...
Low-dose inhaled corticosteroids (ICS) substantially lower the risk for asthma exacerbations and mortality and are therefore essential for every patient with asthma. In everyday practice, a central ...
Please provide your email address to receive an email when new articles are posted on . Adherence was deemed poor, suboptimal or good via the medication possession ratio. A similar proportion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results